Why Did Trevi Therapeutics Plunge 14.63% Amid Investor Conferences?

On April 4, 2025, Trevi Therapeutics experienced a significant drop of 14.63% in pre-market trading, reflecting a notable shift in investor sentiment towards the biopharmaceutical company.

Trevi Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in several upcoming investor conferences in April. The company's senior management, including President and CEO Jennifer Good, will present at key events such as the 24th Annual Needham Virtual Healthcare Conference, the Jones Healthcare and Technology Innovation Conference, and the Piper Sandler Spring Biopharma Symposium. These presentations are expected to provide insights into the company's progress and future plans, particularly focusing on its investigational therapy Haduvio™, which is being developed for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Haduvio™, an oral nalbuphine extended-release therapy, has shown promising results in clinical trials, demonstrating a statistically significant reduction in chronic cough across patients with both IPF and RCC. The therapy acts on the cough reflex arc both centrally and peripherally, targeting kappa and mu opioid receptors to control cough hypersensitivity. This unique mechanism of action positions Haduvio™ as a potential breakthrough treatment for chronic cough, a condition that significantly impacts the quality of life for patients with IPF and RCC.

Trevi Therapeutics' participation in these investor conferences is likely aimed at increasing visibility and attracting potential investors, as the company continues to advance its clinical development programs. The presentations will provide an opportunity for the company to highlight its innovative approach to treating chronic cough and to discuss the potential market opportunities for Haduvio™. The company's focus on addressing unmet medical needs in the treatment of chronic cough is expected to resonate with investors and stakeholders, potentially influencing future stock performance.